Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$36.28 - $75.29 $36,280 - $75,290
-1,000 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$69.73 - $142.9 $34,865 - $71,450
500 Added 100.0%
1,000 $74,000
Q4 2021

Feb 15, 2022

BUY
$134.56 - $217.97 $67,280 - $108,985
500 New
500 $72,000
Q3 2021

Nov 15, 2021

SELL
$177.8 - $270.58 $355,600 - $541,160
-2,000 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$121.0 - $257.67 $242,000 - $515,340
2,000 New
2,000 $425,000
Q1 2021

May 17, 2021

SELL
$112.98 - $319.93 $225,960 - $639,860
-2,000 Closed
0 $0
Q4 2020

Feb 16, 2021

SELL
$78.74 - $139.5 $39,370 - $69,750
-500 Reduced 20.0%
2,000 $223,000
Q3 2020

Nov 13, 2020

BUY
$79.44 - $178.51 $198,600 - $446,275
2,500 New
2,500 $271,000

Others Institutions Holding NVAX

About NOVAVAX INC


  • Ticker NVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,215,104
  • Market Cap $666M
  • Description
  • Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...
More about NVAX
Track This Portfolio

Track Sg3 Management, LLC Portfolio

Follow Sg3 Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sg3 Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sg3 Management, LLC with notifications on news.